UNSPSC 51263164: Levobetaxolol hydrochloride

This classification denotes a beta-adrenergic blocking agent with the molecular formula C18H29NO3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8MR4W4O06J, chemically known as 2-propanol, 1-(4-(2-(cyclopropylmethoxy)ethyl)phenoxy)-3-((1-methylethyl)amino)-, hydrochloride, (2s)- but more generally known as levobetaxolol hydrochloride, which bears US NIH Compound Identifier 60656. Most nations, for tariff and trade purposes, schedule levobetaxolol hydrochloride under HS 29221980.

As of Q4 2014, LEVOBETAXOLOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Levobetaxolol hydrochloride bears US NLM identifiers UMLS ID C0876234 and NCI Concept Code C66007. SMILES: CC(C)NC[C@@H](COC1CCC(CC1)CCOCC2CC2)O.CL.

UNSPSC 51263164 Levobetaxolol hydrochloride is a Commodity code that state and local governments tag for pharmaceutical procurement, though recent solicitation activity under this code shows minimal alignment with the nominal product scope. The single recent opportunity on record—Seminole County, Florida's IFB for Naloxone and Safe Drug Deactivation Systems—is plainly unrelated to levobetaxolol, a beta-blocker eye drop used in glaucoma treatment. The mismatch suggests either miscoding on the county's part or a data artifact in how the opportunity was indexed. No additional recent state and local solicitations appear under this Commodity code in the available opportunities block.

The Seminole County posting (IFB60459723LAS, due July 26, 2023) sought 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The contract carried a two-year initial term with a one-year renewal option, required E-Verify compliance and drug-free workplace certification, and mandated workers' compensation and commercial general liability coverage. Given the absence of additional recent opportunities tagged to this Commodity code and the mismatch between the code's pharmaceutical designation and the naloxone-focused activity observed, this code shows little active state and local procurement momentum in the current period.